Innate Pharma SA (IPHA) Price Prediction & ForecastIPHAInnate Pharma SA

Alphio's IPHA stock price prediction model matches the current Innate Pharma SA tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $2.22 (+0.11%). The 1-week path is $2.07 (-6.69%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.

Innate Pharma SA (IPHA) is a good buy right now due to its recent strategic partnership with Swedish Orphan Biovitrum, which provides an upfront payment of $75 million and potential future earnings of up to $465 million. The stock is currently priced at $2.22, and analysts have set a price target as high as $9, suggesting significant upside potential. However, the forward P/E ratio is currently at 0, indicating that the company is not expected to generate profits in the near term, which is a risk to consider.

Innate Pharma SA (IPHA) last closed at $2.22, losing -0.45%. These facts feed the 1-day and 1-week IPHA price prediction above.